Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
September 16, 2020 11:21 AM EDTUpdated 11:56 AM
Deals
R&D

For­get the IPO, Il­lu­mi­na is near­ing a buy­out of $1.9B liq­uid biop­sy start­up Grail — re­port

Jason Mast

Editor

Grail, the $1.9 bil­lion, Jeff Be­zos-backed liq­uid biop­sy start­up, may not be go­ing pub­lic af­ter all.

Wednes­day morn­ing, a week af­ter the biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times